• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly’s diabetes drugs boost Q1 revenue, earnings

April 25, 2017 By Sarah Faulkner

Eli LillyShares in Eli Lilly (NYSE:LLY) fell slightly today as the company met expectations on Wall Street with its 1st quarter financial results.

The company has faced its share of issues in the last year – Lilly took a $150 million hit in November after its Alzheimer’s drug failed in a clinical trial and this month, the FDA rejected its rheumatoid arthritis drug. But the company’s diabetes therapies, such as Trulicity and Humalog, helped to propel the company to an adjusted quarterly profit that beat expectations on The Street.

“We are encouraged by another solid performance from Lilly’s overall diabetes franchise,” Leerink Partners analyst Seamus Fernandez said in a note, according to Reuters.

The Indianapolis-based company posted a net loss of -$110.8 million, or -10¢ per share, on sales of $5.23 billion for the 3 months ended March 31, for bottom-line loss of -125% on sales growth of 8% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 98¢, ahead of consensus on The Street, where analysts were looking for sales of $5.28 billion.

“Lilly’s new product launches, including Trulicity and Taltz, led the company to a strong quarter of volume-driven revenue growth. We achieved this growth while maintaining our commitment to expand margins and improve productivity,” president & CEO David Ricks said in prepared remarks. “The progress we made in the 1st quarter continues the positive momentum we’ve built over the past few years. We remain on track to sustain a steady flow of innovation that has the potential to improve patients’ lives and create value for shareholders.”

Earnings per share for 2017 are being revised to be in the range of $2.60 to $2.70 on a reported basis, due to severance costs incurred as a result of actions taken to reduce the company’s cost structure. Earnings per share for 2017 are being reaffirmed to be $4.05 to $4.15 on a non-GAAP basis.

Lilly said it expects to post adjusted EPS of $4.05 to $4.15 for 2017.

LLY shares were trading at $81.39 apiece today in morning trading, down -2.4%.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS